Rincazole is being studied for anti-cancer treatment

Modern Biosciences has begun new research as a possible cancer drug, the former schizophrenia drug rimazole has announcedAnti-cancer studies of rincazole focused on sigma-1 receptorsThe receptor was originally thought to be an opioid receptor, and its ligand has the potential to treatof mentaldiseaseIt was not until 1996 when it was cloned that it was found to be homologous at the primary sequence level with traditional opioid receptorsDrBarbara Spruse and his team at the University of Dundee have shown for the first time that drugs such as rincazole that bind to sigma-1 receptors can causetumorscells (and nonnormal cells) tend to apoptosisAbout 20 years ago, there were unsuccessful clinical trials of rincazole for the treatment of schizophrenia, and there is a large amount of preclinical and clinical safety data available, so the development risk is considered lower than that of other generic drugsAccording to Modern Biosciences, the many features of rincazole make it a promising cancer candidateRincazole is a small molecular drug that can be taken orallyIt acts through a dual mechanism of action, which can strongly stimulate apoptosis and inhibit angiogenesis intumorIt can fight a variety of cancers, including those that are resistant to existing drugsIt's low-toxic The company plans to begin Phase I.b trials this year, which will monitor the growth of tumors and a series of biomarkers showing the progression of disease , and proof-of-concept data will be available within two years (Duan Wanru)